TSW
SPRO icon

Three Seasons Wealth’s Spero Therapeutics SPRO Stock Holding History

Three Seasons Wealth’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$70.2K Hold
30,000
– – 0.03% 187
2025
Q4 		$69.9K Hold
30,000
– – 0.01% 188
2025
Q3 		$56.4K Hold
30,000
– – 0.01% 171
2025
Q2 		$87K Hold
30,000
– – 0.01% 112
2025
Q1 		$21.6K Hold
30,000
– – 0.01% 106
2024
Q4 		$30.9K Hold
30,000
– – 0.02% 123
2024
Q3 		$40.2K Buy
30,000
+15,000
+100% +$20.1K 0.02% 107
2024
Q2 		$19.5K Hold
15,000
– – 0.01% 87
2024
Q1 		$27K Hold
15,000
– – 0.02% 80
2023
Q4 		$22.1K Buy
+15,000
New +$17.9K 0.02% 83

Other funds holding SPRO

GP
GSK plc London $599M AUM
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Three Seasons Wealth's SPRO Position: Q1 2026 in Review

Three Seasons Wealth held its Spero Therapeutics (SPRO) position steady in Q1 2026 at 30,000 shares worth $70.2K. The position accounts for 0.03% of the portfolio, ranked #187.

Three Seasons Wealth first reported a position in SPRO in Q4 2023 and has held it in 10 quarters since. The position peaked at $87K in Q2 2025. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • Three Seasons Wealth held 30,000 shares of Spero Therapeutics worth $70.2K as of Q1 2026.
  • Three Seasons Wealth left its Spero Therapeutics share count unchanged in Q1 2026.
  • Spero Therapeutics made up 0.03% of Three Seasons Wealth's portfolio in Q1 2026, its #187 holding.
  • Three Seasons Wealth first reported a position in Spero Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Three Seasons Wealth's Spero Therapeutics position peaked at $87K in Q2 2025.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on Three Seasons Wealth's 13F filing for Q1 2026, filed 5 May 2026.